ArticleThe oncologist2024

Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.

Nicoletta Colombo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.